

G-I-N Conference 2015

Amsterdam, The Netherlands | 7-10 October 2015

Technologies That Improve Systematic Reviews: Rapid Reviews Lose Their Appeal



A joint project between



Sandra Zelman Lewis, PhD



Disclosure of Interests (last 3 years)

Sandra Zelman Lewis, PhD

I certify that, to the best of my knowledge, no aspect of my current personal or professional situation might reasonably be expected to affect significantly my views on the subject on which I am presenting, other than the following:

I am the Chief Guidelines Officer, Doctor Evidence, LLC

President, EBQ Consulting, LLC

I speak publicly on this topic at conferences and other venues

Technologies That Improve Systematic Reviews: Rapid Reviews Lose Their Appeal

Background

Context

Best Practices

Lessons for guideline developers, adapters,
implementers, and other users



A joint project
between



#GIN2015
@GINConference

Background

↑ Demand for rapid reviews (RRs):

- Budget pressures
- Resource constraints (personnel)
- Requirements for accelerated timelines

↓ Confidence in results:

- RRs take liberties in their processes
- Make trade-offs, cut corners
- No standardized methodology
- Comprehensiveness compromised
- Some RRs are narratives only, without analyses
- Even proposing, ““only the most relevant material (determined subjectively by the reviewer) is extracted and presented.”¹

1. Khangura S, Konnyu K, Cushman R, Grimshaw J, Moher D. Evidence summaries: the evolution of a rapid review approach. *Systematic Reviews*. 2012;1(10):1-9.



Requirements for Good Evidence Reviews

- Systematic
- Objective
- With uncompromised validity
- No interjected biases^{2,3}

Researchers advise considering RRs interim guidance until thorough SRs can be performed.⁴

2. Schünemann HJ, Moja L. Reviews: Rapid! Rapid! Rapid! ...and systematic. *Systematic Reviews*. 2015;4(4).

3. Hartling L, Guise JM, Kato E, et.al. *EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews*. Research White Paper (Prepared by the Scientific Resource Center under Contract No. 290-2012-00004-C.) AHRQ Publication No. 15-EHC008-EF. Rockville, MD. <http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.2015>.

4. National Collaborating Centre for Methods and Tools. Methods: Synthesis 1. Rapid reviews: Methods and implications. [fact sheet]. Hamilton, ON: National Collaborating Centre for Methods and Tools. http://www.nccmt.ca/pubs/Methods_Synthesis1.pdf.

Today's Context

Technologies provide:

- Efficiencies of time and resources
- Scalable/updatable
- Transparencies of data and methods
- Without compromising:
 - Integrity
 - Quality
 - Comprehensiveness
 - Reliability³

Range:

- Fabricated collages of software products
 - Importing and exporting
 - Tools without support
- Sleek integrated solutions for dynamically updatable SRs

3. Hartling L, Guise JM, Kato E, et.al. *EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews. Research White Paper (Prepared by the Scientific Resource Center under Contract No. 290-2012-00004-C.) AHRQ Publication No. 15-EHC008-EF.* Rockville, MD.

<http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.2015>.



Today's Best Practices

Digital technologies feature:

- High quality with transparent data and methods
- Time-efficient
- Human-oversight and software-assisted (OCR) data extractions
 - Electronic data capture from tables, graphs, charts (natural language processing more manual from narratives)
 - Near pristine, error-free quality
 - **Digitized data from all primary studies for analyses and ease of updating (only way to keep SRs updatable)**
 - Enriched statistical analytic capabilities
- Integrated functionalities for an end-to-end solution
 - Negates need for imports/exports
 - Eliminates data corruption
- Synonym management, after extraction
 - Combine like terms as appropriate for specific PICO
 - Maintain unique terms as appropriate

Today's Best Practices

Benefits of digitized data:

- Maintain currency as new evidence is published
 - Ease of updating
 - Efficiency: within days
 - Without requiring *de novo* reviews for each update
 - Living guidelines made possible
- Quality assessments
 - Study level
 - By outcome across studies

Outcomes		Methotrexate / Adalimumab (N = 268)	Methotrexate / Placebo (N = 257)	P-Value	
ACR, 20	0 yr / 1 yr	196 (73)	162 (63)	0.022	IM
	0 yr / 2 yr	185 (69)	144 (56)	0.002	IM
ACR, 50	0 yr / 1 yr	166 (62)	118 (46)	< 0.001	IM
	0 yr / 2 yr	158 (59)	111 (43)	< 0.001	IM
ACR, 70	0 yr / 1 yr	123 (46)	72 (28)	< 0.001	IM
	0 yr / 2 yr	126 (47)	72 (28)	< 0.001	IM
ACR, 90	0 yr / 1 yr	64 (24)	33 (13)	< 0.001	IM
	0 yr / 2 yr	72 (27)	33 (13)	< 0.001	IM
Adverse Event, Any	0 yr / 2 yr	262 (97.8)	245 (95.3)		IM
Adverse Event, Severe, PPY		18.5 / 100 person-years	15.9 / 100 person-years		IM
Cancer, PPY		0.4 / 100 person-years	0.9 / 100 person-years		IM
Cancer, Any	0 yr / 2 yr	2 (0.7)	4 (1.6)		IM
Cancer, Breast	0 yr / 2 yr	0 (0)	1 (0.4)		IM

Today's Best Practices

Benefits of digitized data:

- Facilitate complex state-of-the-art analyses
 - Meta analyses: direct, indirect, Bayesian NMAs
 - Sensitivity analyses
 - Subgroup analyses

Bayesian Analysis Wizard

Random-Effects Model, $I^2 = 81$, Tau² estimator: DL

tau² (estimated amount of total heterogeneity): 0.0027 (SE = 0.0010)

I² (approx. prop. of heterogeneity due to chance): 81.98%

I² (total heterogeneity / total variability): 81.98%

tau² (total variability / sampling variability): 0.40

Treatment	Label
Methotrexate + Infliximab	Methotrexate + infliximab
Methotrexate + Placebo	Methotrexate + Placebo
Methotrexate + Etanercept	Methotrexate + Etanercept
Methotrexate/Etanercept	Methotrexate/Etanercept
Methotrexate/Placebo	Methotrexate/Placebo


Please provide a short label for each of the treatments. The labels cannot contain special characters or spaces. Treatments with the same label are automatically grouped. Optionally, select a baseline treatment for which to calculate the relative effects.

Make sure all treatments are connected. You can (de)select the treatments by clicking the nodes. The size of the nodes indicates the sample size, the width of the edges the number of comparing studies.



Today's Best Practices

Benefits of digitized data:

- Sophisticated visualizations
 - Evidence tables
 - Frequency reports: characteristics and outcomes across studies
 - Refined image presentations
 - Transform in real time to
 - Display study characteristics by year of publication, PICO elements, or any chosen descriptor



Author	Year	Title	Design
van Herwaarden BF	2011	Abacavir in patients with rheumatoid arthritis and an inadequate response to methotrexate treat...	RCT
van Herwaarden BF	2012	Tofacitinib or abataceptim versus placebo in rheumatoid arthritis	ACT
Miyasaka H	2008	Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adal...	RCT
Ahn H Y	2007	A randomized, double-blind, placebo-controlled, phase II study of the tumor necrosis factor...	RCT
Han H Y	2007	A randomized, double-blind, placebo-controlled, phase II study of the tumor necrosis factor...	RCT
Jamal S	2009	Abataceptim response in patients with early versus established rheumatoid arthritis: DEIRA res...	Sub-group Analysis



Lessons Learned

To maximize the value and benefits of digital technologies:

- Volunteers workflow changes
 - Traditional approach: Without dedicated staff resources, the review could take 6 months or more.
 - New Technology approach: Use volunteer's expertise more and burden them with the tedious work less
 - Clinical and methods experts collaborating on protocol prep (eg, PICOTSS and analyses plans)
 - Post-publication: Volunteers should be COI-approved and ready for updating in case of potential monitored literature alerts

Lessons Learned

To maximize the value and benefits of digital technologies:

- Staffing workflow changes
 - Same volume of staff to coordinate more guidelines
 - Reduced burden, tedious work
 - Time efficiencies move project more quickly
 - Arrange COI-approved panel in advance (maintain for future updates)
 - Anticipate possible literature monitoring alerts



Lessons Learned

To maximize the value and benefits of digital technologies:

- Budget with forethought
 - Anticipate access fees and project-specific costs
 - Variable based on volume of literature, number of studies screened in (in some programs, *eg*, GROWTH, pre-digitized studies provided to members free), and potential need for methodology services)
 - Budget for updates based on literature alerts/preliminary analyses
- Leadership
 - Innovative leaders
 - Knowledgeable about technology solutions, able to discuss
 - Prepared to enter into collaborative arrangements (MOUs) with other guideline-developing organizations

Lessons Learned

Properly configured technology-assisted SRs have

- Maximum rigor
- Reliability
- Accuracy
- Scalability
- But can be completed in a fraction of the time of standard reviews

Therefore, short-cut rapid reviews are no longer necessary.

Allows more time to engage all stakeholders, incorporate qualitative evidence, and formulate recommendations.

With advanced knowledge management, reviews and guidelines can be quickly and easily updated and kept living.





Sandra Zelman Lewis, PhD
slewis@doctorevidence.com



A joint project between



Thank you for your attention!